Business
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and hav
About this update from Collegium Pharmaceutical, Inc.
[{"type":"image","alt":"Dyne Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dyne Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nro7S6xW_IUN_DBx15qegw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39","width":300,"height":91}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics.","length":598,"tagName":"p"},{"type":"text","content":"“We are pleased to welcome Vikram to our Board as we advance toward commercialization,” said Jason Rhodes, chairman of Dyne’s Board of Directors and partner at Atlas Venture. “As a CEO and former commercial leader of a biotechnology company that grew quickly and successfully, Vikram brings valuable experience in launching products, driving growth, and realizing value. His insights will further Dyne’s progress toward generating revenue and expanding our portfolio.”","length":468,"tagName":"p"},{"type":"text","content":"“Throughout my career, I’ve focused on translating innovation into highly successful businesses that unlock value and improve the lives of patients,” said Vikram Karnani. “Dyne’s clinically validated drug delivery approach and progress towards commercialization underscore its potential to deliver meaningful functional improvement for people living with neuromuscular diseases. I’m excited to join the Board at this pivotal stage as the company works to realize its full potential and build shareholder value.”","length":511,"tagName":"p"},{"type":"text","content":"“Vikram’s track record of running world-class commercial and medical organizations will a...